7. License Agreements (Details Narrative) - Weg License Agreement [Member] - USD ($)	1 Months Ended
	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020	Aug. 31, 2019	Mar. 31, 2022
Business Combination, Separately Recognized Transactions [Line Items]
Business Combination, Separately Recognized Transactions, Description				On August 29, 2019, the Company entered into an amended and restated exclusive license agreement with Stuart Weg, M.D. (the “Weg License Agreement”), pursuant to which the Company was granted an exclusive worldwide license to certain intellectual property and regulatory materials related to SLS-002. Under the terms of the Weg License Agreement, the Company paid an upfront license fee of $75,000 upon execution of the agreement. The Company agreed to pay additional consideration to Dr. Weg as follows: (i) $0.1 million on January 2, 2020, (ii) $0.125 million on January 2, 2021, and (iii) in the event the FDA has not approved an NDA for a product containing ketamine in any dosage on or before December 31, 2021, $
[custom:NonrefundableCashPayment]	$ 200,000	$ 125,000	$ 100,000
Asset Acquisition, Contingent Consideration, Liability, Current					$ 0